Compare ARK Innovation ETF (ARKK) vs ClearPoint Neuro Inc (CLPT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs ClearPoint Neuro Inc — how do they compare? ARK Innovation ETF trades at $80.89, while ClearPoint Neuro Inc trades at $15.2 (market cap $454.21M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | CLPT | |
|---|---|---|
52-Week High | $92.50 | $29.60 |
52-Week Low | $63.52 | $8.66 |
Market Cap | — | $454.21M |
Sector | — | Health |
Enterprise Value | — | $488.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $81.37, up 1.13% with a bullish technical signal from moving averages. The fund faces mixed sentiment with Seeking Alpha highlighting concentration risks and underperformance versus S&P 500, while Cathie Wood continues aggressive buying in AI stocks like CoreWeave. Technical indicators show overbought conditions with RSI at 91 on the 6-day timeframe.
Outlook remains challenged by high fees (0.75%), concentrated bets on Tesla and SpaceX, and limited AI exposure. The fund's venture-style approach creates volatility, with 37.88% losses over five years. Near-term performance hinges on Tesla's 10% weighting and AI stock momentum amid decelerating revenue growth in portfolio companies.
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →
